Microsoft said on Tuesday its first data center in Mount Pleasant, Wisconsin — the Fairwater campus — is complete and fully operational. Equipment went online and commissioning finished in April; construction was announced in May 2024. Nearly 10,000 construction workers participated over the past two years and the project finished ahead of schedule. The site currently has about 550 full‑time employees supporting operations; Microsoft and its contractors are actively recruiting and expect headcou

Sinovac Biotech’s fully human anti-tetanus monoclonal antibody SNA02-48 injection has entered a Phase III trial, with the first volunteer enrolled at Shenzhen Second People’s Hospital. SNA02-48 was cleared for clinical use in March 2025 and is a recombinant fully human mAb for emergency post-exposure prophylaxis against tetanus. Sinovac is expanding a wound-care portfolio covering active and passive immunity: its adsorbed tetanus vaccine is market-approved; Sinovac-backed Xingmeng Biotech’s Class 1 innovative drug Krebi® (monoclonal antibody injection) is approved for passive immunization of adults exposed to rabies; Sinovac’s lyophilized human rabies vaccine (serum-free Vero cell) is in the regulatory filing stage.

IRNA reports Iran and Oman have agreed to form a Strait of Hormuz committee.